High Serum Adipocyte Fatty Acid Binding Protein Is Associated with Metabolic Syndrome in Patients with Type 2 Diabetes.
Jer-Chuan LiDu-An WuJia-Sian HouYi-Maun SubeqHsin-Dean ChenBang-Gee HsuPublished in: Journal of diabetes research (2016)
Adipocyte fatty acid binding protein (A-FABP) is a key mediator of obesity-related metabolic syndrome (MetS). The aim of this study was to evaluate the relationship between A-FABP concentration and MetS in type 2 diabetes mellitus (DM) patients. Fasting blood samples were obtained from 165 type 2 DM volunteers. MetS and its components were defined using diagnostic criteria from the International Diabetes Federation. Among 165 DM patients, 113 patients (68.5%) had MetS. Diabetic persons who had MetS had significantly higher A-FABP levels (P < 0.001) than those without MetS. Female DM persons had higher A-FABP level than man (P < 0.001). No statistically significant differences in A-FABP levels were found in use of statin, fibrate, or antidiabetic drugs. Multivariate forward stepwise linear regression analysis revealed that body fat mass (P < 0.001), logarithmically transformed creatinine (log-creatinine; P < 0.001), female DM patients (P < 0.001), and logarithmically transformed high sensitive C-reactive protein (log-hs-CRP; P = 0.013) were positively correlated, while albumin (P = 0.004) and glomerular filtration rate (GFR; P = 0.043) were negatively correlated with serum A-FABP levels in type 2 DM patients. In this study, higher serum A-FABP level was positively associated with MetS in type 2 DM patients.
Keyphrases
- end stage renal disease
- metabolic syndrome
- binding protein
- newly diagnosed
- ejection fraction
- chronic kidney disease
- fatty acid
- peritoneal dialysis
- insulin resistance
- type diabetes
- prognostic factors
- adipose tissue
- cardiovascular disease
- patient reported outcomes
- body mass index
- coronary artery disease
- glycemic control
- uric acid
- cardiovascular risk factors
- drug induced
- data analysis